The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: Results of the multi-centre CHAMPS trial

Winfred C. Wang, Carlo Brugnara, Cathie Snyder, Lynn Wynn, Zora Rogers, Karen Kalinyak, Clark Brown, Asif Qureshi, Carolyn Bigelow, Lynne Neumayr, Kim Smith-Whitley, David H K Chui, Mardee Delahunty, Rob Woolson, Martin Steinberg, Marilyn Telen, Karen Kesler

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

In a phase-II multi-centre double-blinded trial, we evaluated haematological effects of oral hydroxycarbamide (HC) and magnesium (Mg) in patients with HbSC, aged 5-53years old. Subjects were randomized to HC+placebo, Mg+placebo, HC+Mg, or placebo+placebo. The primary endpoint was the proportion of hyperdense red blood cells after 8weeks. Thirty-six subjects were evaluable, but the study was terminated early because of slow enrollment. In the combined HC groups, mean cell volume and HbF were increased, but differences were not seen in hyperdense red cells or vaso-occlusive events. Mg had no effects. Further investigation of hydroxycarbamide as monotherapy in HbSC disease is warranted.

Original languageEnglish (US)
Pages (from-to)771-776
Number of pages6
JournalBritish Journal of Haematology
Volume152
Issue number6
DOIs
StatePublished - Mar 2011

Keywords

  • Hb SC disease
  • Hydroxycarbamide
  • Hydroxyurea
  • Magnesium
  • Sickle cell

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: Results of the multi-centre CHAMPS trial'. Together they form a unique fingerprint.

Cite this